[EN] 2,3,5 TRISUBSTITUTED ARYL AND HETEROARYL AMINO DERIVATIVES, COMPOSITIONS, AND METHODS OF USE [FR] DÉRIVÉS AMINÉS D'HÉTÉROARYLE ET D'ARYLE 2,3,5 TRISUBSTITUÉS, COMPOSITIONS ET PROCÉDÉS D'UTILISATION ASSOCIÉS
Thermolyse von O,O-dialkyl-S-aryl-thiophosphorsäureestern
作者:K. Pilgram、F. Korte
DOI:10.1016/s0040-4020(01)98339-5
日期:1965.1
O,O-Dialkyl-S-aryl-phosphorothioates are thermally unstable and decompose readily at a temperature of about 150° with formation of alkyl aryl sulfides and polymeric alkyl meta- or -polyphosphates. Differences in reactivity within a series of 33 phosphorothioates are rationalized on the basis of steric and electromeric effects. The mechanism of the thermal degradation is discussed, the influence of
The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
Heterobicyclic Metalloprotease Inhibitors
申请人:STEENECK Christoph
公开号:US20090312312A1
公开(公告)日:2009-12-17
The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
HETEROBICYCLIC METALLOPROTEASE INHIBITORS
申请人:Steeneck Christoph
公开号:US20120015920A1
公开(公告)日:2012-01-19
The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.